Plain-English translation of NCT07230613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new way to treat stage III melanoma by injecting two immunotherapy medications called ipilimumab and nivolumab directly into the tumor itself, rather than through the entire body. The goal is to get stronger results with fewer side effects by concentrating the medication where it's needed most. Surgery to remove the tumor happens after the injections.
Previous studies showed that giving these two medications through the bloodstream works better than treatment after surgery, but it causes severe side effects in about 30% of patients. This trial is exploring whether injecting the medication directly into the tumor could give the same benefit with fewer problems.
You likely qualify if…
You likely don't qualify if…
You will receive up to three injections of the medication directly into your melanoma tumor, spaced three weeks apart over about six weeks. Between injections, your doctors will monitor how your tumor responds. After completing the injections, you will have surgery to remove the melanoma. Throughout the study, your medical team will collect blood and tumor samples to understand how the treatment is working and to identify which patients benefit most.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France